A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Phase 2
120
about 3.2 years
18–130
14 sites in AZ, CA, DC +11
What this study is about
This trial is testing the safety and effectiveness of new treatments for colorectal cancer. Participants will be randomly assigned to receive different combinations of medications, including Volrustomig, FOLFIRI (a chemotherapy drug), and Bevacizumab (an anti-cancer drug). It aims to evaluate how well these interventions work in people with advanced or metastatic colorectal cancer who have not received previous treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Bevacizumab
- 2.Take FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)
- 3.Take Volrustomig
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
bevacizumab, chemotherapy (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), irinotecan, Antidotes, Deterrents, and Toxicologic Agents (Enzyme Interactions)
infusion, injection (Injection), oral (Oral Capsule)
Primary: Number of Participants with Adverse Events (AEs), Progression Free Survival (PFS)
Secondary: Disease Control Rate (DCR), Duration of Response (DOR), Maximum Observed Concentration (Cmax), Objective Response Rate (ORR), Overall Survival (OS), Time to second progression or death (PFS2)
Oncology